Close
Close

Center Trials & Treatment - Melanoma Recurrent

Partner

Not provided

Rare Disease

Melanoma Recurrent

Sponsor

Center Trials & Treatment

Access Program Information

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

Contact

Contact: Ivo Reznic, PhD (+ 48 508 786 670)

Locations
  • Belarus
  • Hong Kong
  • Tajikistan
  • Uzbekistan

Free Newsletter